As usual, biotech is continuing to see significant growth in the Bay State capital, with several hefty venture rounds going to companies that aim to keep humans healthy. Most notably, a biotech company in the neuromedicinal space raised a nine-figure sum. Read on to learn more about the company that snagged August’s biggest round.
Top Boston Tech Funding Rounds, August 2023
- Rapport Therapeutics
- Lightforce Orthodontics
- Solu Therapeutics
- FIGUR8
- Akkio
#5. $15 million, August 1
Operating in the generative AI space, Akkio helps businesses automatically generate insights, visualizations and dashboards from their data. The company announced a round of Series A funding from investors including Bain Capital Ventures and Pandome. Akkio plans to invest in scaling its team and advancing its tech platform.
#4. $25 million, August 8
Biotech company FIGUR8 wants to standardize musculoskeletal health and injury recovery data. After securing a round of A-1 funding led by First Spark Ventures, FIGUR8 plans to drive growth and adoption of its core bioMotion assessment platform. The tool gathers biomechanics data captured in clinical settings.
#3. $31 million, August 1
Solu Therapeutics is working to develop therapeutics to eliminate disease-driving cells in cancer, immunology and autoimmunity. The company secured an oversubscribed seed funding round from lead investors Longwood and Santé Ventures. With the money, Solu plans to leverage and develop a proprietary cytotoxicity targeting chimera platform and drug candidates.
#2. $80 million, August 3
The company’s solution equips orthodontists with the tools they need to build customized 3D-printed braces for their patients. Ally Bridge Group led the company’s latest funding round that will help Lightforce expand its manufacturing capabilities. It also has plans to scale its operations and hire new talent across sales and manufacturing.
#1. $150 million, August 23
Biotech company Rapport leverages the science of receptor-associated proteins to develop precision neuromedicines. The company announced a hefty round of Series B capital spearheaded by Cormorant Asset Management, that will help it advance its ongoing clinical programs in seizure and psychiatric disorders, as well as expand its pipeline of treatments.
